The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer.
J. Cassidy
Consultant or Advisory Role - Amgen; Roche; Sanofi
Honoraria - Amgen; Roche; Sanofi
Research Funding - Amgen; Roche; Sanofi
J. O'Shaughnessy
Consultant or Advisory Role - Roche
Honoraria - Roche
H. Schmoll
No relevant relationships to disclose
C. Twelves
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - conference eg ASCO travel
T. H. Cartwright
Consultant or Advisory Role - Roche
Honoraria - Roche
A. Buzdar
Research Funding - Roche
E. McKenna
Employment or Leadership Position - Genentech
F. Gilberg
Employment or Leadership Position - Roche
N. Scotto
Employment or Leadership Position - Roche
D. G. Haller
Consultant or Advisory Role - Roche